Fulcrum Therapeutics (FULC) Receivables - Accured (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Receivables - Accured data on record, last reported at $1.8 million in Q1 2026.

  • On a quarterly basis, Receivables - Accured rose 13.7% to $1.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.8 million, a 13.7% increase, with the full-year FY2025 number at $1.1 million, down 14.13% from a year prior.
  • Receivables - Accured reached $1.8 million in Q1 2026 per FULC's latest filing, up from $1.1 million in the prior quarter.
  • Over the last five years, Receivables - Accured for FULC hit a ceiling of $1.8 million in Q1 2026 and a floor of $392000.0 in Q2 2022.
  • A 5-year average of $1.1 million and a median of $1.2 million in 2023 define the central range for Receivables - Accured.
  • Peak YoY movement for Receivables - Accured: surged 298.04% in 2022, then crashed 40.66% in 2025.
  • Tracing FULC's Receivables - Accured over 5 years: stood at $852000.0 in 2022, then skyrocketed by 100.94% to $1.7 million in 2023, then decreased by 27.22% to $1.2 million in 2024, then decreased by 14.13% to $1.1 million in 2025, then surged by 65.98% to $1.8 million in 2026.
  • Business Quant data shows Receivables - Accured for FULC at $1.8 million in Q1 2026, $1.1 million in Q4 2025, and $934000.0 in Q3 2025.